Phase 2 N=162 Trial of Poor Performance Status Patients (ToPPS)
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.8; 4.0; 4.8 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=64 Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
Lung Cancer
Primary: Objective Response Rate (OR) Where OR=CR+PR: Number of Participants With Responses of Complete Response (CR) and Partial Response (PR) — 3 Participants
Phase 2 N=16 Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
Stage IV Non-Small Cell Lung Cancer
Primary: Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung…
N/A N=364 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment
Lymphoma · Digestive System Diseases · Ovarian Diseases
Primary: Number of Participant Deaths — 56 Participants
N/A N=306 Advancing Symptom Alleviation With Palliative Treatment
Heart Failure · Pulmonary Disease, Chronic Obstructive · Emphysema
Primary: Function Assessment of Chronic Illness Therapy-General (FACT-G) — 59.0; 54.0 score on a scale
N/A N=43 Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Patient Global Impression of Severity (PGI-S) Score in Cohort A Participants at Approximately 30 Minutes of Previous Dose of Inhaled Treprostinil…
N/A N=90 An Intervention to Improve Function in Severe Cardiopulmonary Illness
Chronic Obstructive Pulmonary Disease (COPD) · Heart Failure
Primary: Function Capability — 349; 338 meters
Phase 2 N=105 Taxol Carboplatin and Erythropoetin
Ovarian Cancer
Primary: Progression-free Survival. Progression is Defined According WHO-criteria as Appearance of Any New Lesion or Increase of Existing Lesions by at Least 25% — 28.8 months
N/A N=469 Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer
Sarcopenia · Non Small Cell Lung Cancer · Malnutrition
Primary: Progression Free Survival (PFS) — 350; 773 days
Phase 4 N=42 Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)
Heart Failure
Primary: Change in Peak VO2 (Oxygen Consumption ) — 1.21; 0.48 ml/kg/min
N/A N=65 Does Pulmonary Rehabilitation Improve Frailty?
Disease, Pulmonary
Primary: Number of Participants With Frailty Phenotype at Baseline and 6 Months — 24; 15 Participants — p=0.62
N/A N=15 Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices
Heart Failure
Primary: Peak Oxygen Uptake — 15 ml/kg/min
N/A N=17 A Physical Activity Program in End-state Liver Disease
End-stage Liver Disease (ESLD) · Liver Transplant · Sarcopenia
Primary: Physical Fitness - VO2 — -1; -3 mL oxygen/kg/min — p=0.49
N/A N=40 Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer
Lung Neoplasm Malignant
Primary: Overall Step Count — 4707; 5605; 4606 Steps
N/A N=349 Impact of Heart Failure Center Program on Cardiac Outcomes in Patients With Heart Failure
Death · Congestive Heart Failure
Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…
N/A N=10,256 Symptom Management Implementation of Patient Reported Outcomes in Oncology
Other Cancer · Gastrointestinal Cancer · Thoracic Cancer
Primary: Emergency Department Treat/Release [EDTR] Event Occurrence Status at Day 30 — 5.8; 6.9; 5.3; 5.8 percentage of patients with event — p=0.214
N/A N=55 Phase I Study of Accelerated Hypofractionated Image-Guided Radiation Therapy
Non-small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicity — 1; 1; 1 Participants
N/A N=288 Lay Health Worker Led Symptom Assessment Intervention
Cancer
Primary: Edmonton Symptom Assessment Scale Score (ESAS) — 9.6; 7.2 score on a scale
N/A N=398 Life 2: Improving Fitness and Function in Elders
Aging · Mobility Limitations
Primary: Usual Gait Speed — 1.03; 1.03 meters/second
Phase 2 N=227 SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
Cachexia
Primary: Mean Change From Baseline to Day 85 in the Distance Walked During the 6 Minute Walk Test (MWT) Following Treatment With SUN11031 in Participants Having Cachexia…
N/A N=50 HRQoL in the Low MELD Pre-tx Population
Cirrhosis of the Liver
Primary: Perceived HRQoL Score. Overall Qualty of Life Index Tool Was Utilized. — 20.19 scores on a scale
N/A N=109 COPD Access to Pulmonary Rehabilitation Intervention
COPD
Primary: Physical Activity Measured as Change in Average Daily Step Count — 1302.34; -108.15 steps per day — p=0.005
N/A N=80 Peak Inspiratory Flow Rates in Patients With COPD
COPD
Primary: Occurrence of Suboptimal PIFR — 22.7 percentage of participants
N/A N=235 Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience
Fatigue · Self Efficacy · Quality of Life
Primary: Cancer-related Fatigue Severity Using The Brief Fatigue Inventory. — 0.56; 4.19; 4.93 Scores on a scale
N/A N=1,858 Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
Pulmonary Disease, Chronic Obstructive
Primary: Percentage of Participants With "Therapeutic Success" — 48.90; 51.10 Percentage of participants
N/A N=88 Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)
Heart Failure, Diastolic · Obesity
Primary: Peak Exercise Oxygen Consumption (VO2) — 1609; 1653 ml/min — p=0.21
N/A N=56 In-Home Care for Patients With PSP and Related Disorders
Progressive Supranuclear Palsy · Dementia With Lewy Bodies · Multiple System Atrophy
Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59
N/A N=381 Statin Discontinuation in Advanced Illness
Palliative Medicine · Cardiovascular Disease
Primary: Proportion of Deaths Within 60 Days of Enrollment. — 0.203; 0.238 proportion of deaths
N/A N=450 Access to Care and Prognosis in Elderly With Cancer (INCAPAC Study)
Cancer
Primary: Proportion of Patients Being Receiving Treatment Administration After Diagnosis — 372 Participants
Phase 4 N=28 The Effects of Ambrisentan on Exercise Capacity in Fontan Patients
Single Ventricle Fontan Palliation
Primary: Change in VO2 Max — 1.33; 0.745 Change in ml/kg min